Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 6/20 | 0.37 |
| ▸ | DPP4 | P27487 | 9/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.34 |
| ▸ | SKP1 | P63208 | 1/20 | 0.34 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14723078 | 1.00 | RET (0.37) | RETDPP4DPP8DPP7DPP9 | |
| SCHEMBL14723148 | 0.92 | CKS1B (0.38) | RETDPP4DPP8DPP7DPP9 | |
| SCHEMBL14722263 | 0.90 | NTRK1 (0.43) | RETDPP4SMO | |
| SCHEMBL14730278 | 0.90 | NTRK1 (0.43) | RETDPP4SMO | |
| SCHEMBL14730330 | 0.83 | NR1H2 (0.40) | RETDPP4DPP8DPP7DPP9 | |
| SCHEMBL14723221 | 0.83 | NR1H2 (0.40) | RETDPP4DPP8DPP7DPP9 | |
| SCHEMBL24033326 | 0.83 | CKS1B (0.38) | RETSMOCKS1BSKP1SKP2 | |
| SCHEMBL30181528 | 0.83 | CKS1B (0.38) | RETSMOCKS1BSKP1SKP2 | |
| SCHEMBL24817639 | 0.82 | JAK3 (0.40) | RETSMOCKS1BSKP1SKP2 | |
| SCHEMBL14730294 | 0.82 | NTRK1 (0.42) | RETDPP4DPP8DPP9SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013026587-A1 | 1,4 DISUBSTITUTED PYRROLIDINE - 3 - YL -AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2013-02-28 | — | — | WO | disclosed |